PeptideOS
← Library

Liraglutide

GLP-1 agonist

Also known as: Saxenda, Victoza

Tier 1, Approved, characterised

Approved by at least one major regulator for a defined indication, with published human pharmacokinetics and a prescribing label. Well-characterised does not mean risk-free, read the label warnings.

Half-life
13.00 hours · human data · subcutaneous

Elimination half-life ~13 h; maximum concentrations reached ~11 h post-dose (Saxenda label). Once-daily dosing.

Model a dosing schedule →
Dosing
600 - 3000 mcg

Saxenda (obesity): 0.6 mg start to 3.0 mg maintenance per day. Victoza (T2DM) maintenance is 1.2-1.8 mg/day.

Titration
Week 1: 0.6 mg; Week 2: 1.2 mg; Week 3: 1.8 mg; Week 4: 2.4 mg; Week 5 and onward: 3.0 mg (Saxenda).
Frequency
Once daily
Timing
Any time of day, without regard to meals
Regulatory status
FDA-approved (Saxenda for chronic weight management; Victoza for type 2 diabetes).
Evidence base
human clinical · confidence: high

FDA prescribing information (DailyMed) and large phase 3 trials; high quality.

Storage

Lyophilised: Not applicable, supplied as a pre-filled multi-dose solution pen (not lyophilized).

Reconstituted: Refrigerate 2-8°C before first use; protect from light. Pre-filled solution pen; no reconstitution.

Safety

BOXED WARNING: Risk of thyroid C-cell tumors. Liraglutide causes dose- and duration-dependent thyroid C-cell tumors in rodents. Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Also: pancreatitis, gallbladder disease, hypoglycemia with insulin secretagogues.

Sources